Annual EBIT
-$33.02 M
+$26.25 M+44.29%
March 31, 2024
Summary
- As of February 23, 2025, VTGN annual earnings before interest & taxes is -$33.02 million, with the most recent change of +$26.25 million (+44.29%) on March 31, 2024.
- During the last 3 years, VTGN annual EBIT has fallen by -$15.10 million (-84.28%).
- VTGN annual EBIT is now -370922.47% below its all-time high of -$8900.00, reached on December 31, 2010.
Performance
VTGN EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$15.12 M
-$893.00 K-6.28%
December 31, 2024
Summary
- As of February 23, 2025, VTGN quarterly earnings before interest & taxes is -$15.12 million, with the most recent change of -$893.00 thousand (-6.28%) on December 31, 2024.
- Over the past year, VTGN quarterly EBIT has dropped by -$2.99 million (-24.64%).
- VTGN quarterly EBIT is now -3030.23% below its all-time high of $516.00 thousand, reached on December 31, 2013.
Performance
VTGN Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$52.84 M
-$7.24 M-15.87%
December 31, 2024
Summary
- As of February 23, 2025, VTGN TTM earnings before interest & taxes is -$52.84 million, with the most recent change of -$7.24 million (-15.87%) on December 31, 2024.
- Over the past year, VTGN TTM EBIT has dropped by -$14.68 million (-38.48%).
- VTGN TTM EBIT is now -2401581.82% below its all-time high of -$2200.00, reached on March 31, 2007.
Performance
VTGN TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
VTGN EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +44.3% | -24.6% | -38.5% |
| 3 y3 years | -84.3% | -24.6% | -38.5% |
| 5 y5 years | -34.4% | -24.6% | -38.5% |
VTGN EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -84.3% | +44.3% | -123.0% | +23.5% | -60.0% | +18.1% |
| 5 y | 5-year | -84.3% | +44.3% | -384.4% | +23.5% | -252.9% | +18.1% |
| alltime | all time | <-9999.0% | +44.3% | -3030.2% | +65.3% | <-9999.0% | +35.2% |
VistaGen Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | - | -$15.12 M(+6.3%) | -$52.84 M(+15.9%) |
| Sep 2024 | - | -$14.23 M(+17.3%) | -$45.60 M(+19.5%) |
| Jun 2024 | - | -$12.13 M(+6.8%) | -$38.15 M(+15.5%) |
| Mar 2024 | -$33.02 M(-44.3%) | -$11.36 M(+44.1%) | -$33.02 M(-2.6%) |
| Dec 2023 | - | -$7.88 M(+16.3%) | -$33.90 M(-5.3%) |
| Sep 2023 | - | -$6.78 M(-3.1%) | -$35.78 M(-23.0%) |
| Jun 2023 | - | -$7.00 M(-42.8%) | -$46.49 M(-21.5%) |
| Mar 2023 | -$59.27 M(+24.1%) | -$12.24 M(+25.3%) | -$59.26 M(-7.0%) |
| Dec 2022 | - | -$9.77 M(-44.2%) | -$63.71 M(-1.2%) |
| Sep 2022 | - | -$17.49 M(-11.5%) | -$64.48 M(+7.9%) |
| Jun 2022 | - | -$19.77 M(+18.4%) | -$59.78 M(+25.2%) |
| Mar 2022 | -$47.76 M(+166.5%) | -$16.69 M(+58.4%) | -$47.76 M(+28.1%) |
| Dec 2021 | - | -$10.54 M(-17.7%) | -$37.28 M(+16.4%) |
| Sep 2021 | - | -$12.79 M(+65.3%) | -$32.04 M(+42.2%) |
| Jun 2021 | - | -$7.74 M(+24.7%) | -$22.54 M(+25.8%) |
| Mar 2021 | -$17.92 M(-13.7%) | -$6.21 M(+17.3%) | -$17.92 M(+19.7%) |
| Dec 2020 | - | -$5.30 M(+60.9%) | -$14.97 M(-4.2%) |
| Sep 2020 | - | -$3.29 M(+5.5%) | -$15.63 M(-11.5%) |
| Jun 2020 | - | -$3.12 M(-4.3%) | -$17.67 M(-14.9%) |
| Mar 2020 | -$20.76 M(-15.6%) | -$3.26 M(-45.3%) | -$20.76 M(-10.6%) |
| Dec 2019 | - | -$5.96 M(+11.8%) | -$23.22 M(-5.1%) |
| Sep 2019 | - | -$5.33 M(-14.1%) | -$24.47 M(-7.9%) |
| Jun 2019 | - | -$6.20 M(+8.4%) | -$26.57 M(+8.1%) |
| Mar 2019 | -$24.58 M(+76.7%) | -$5.72 M(-20.7%) | -$24.58 M(+1.3%) |
| Dec 2018 | - | -$7.21 M(-2.9%) | -$24.26 M(+23.6%) |
| Sep 2018 | - | -$7.43 M(+76.5%) | -$19.63 M(+16.1%) |
| Jun 2018 | - | -$4.21 M(-22.1%) | -$16.91 M(+13.0%) |
| Mar 2018 | -$13.91 M(+41.6%) | -$5.40 M(+108.5%) | -$14.97 M(+23.6%) |
| Dec 2017 | - | -$2.59 M(-45.1%) | -$12.11 M(+2.7%) |
| Sep 2017 | - | -$4.71 M(+108.5%) | -$11.79 M(+16.0%) |
| Jun 2017 | - | -$2.26 M(-11.3%) | -$10.16 M(+3.4%) |
| Mar 2017 | -$9.82 M(-78.9%) | -$2.55 M(+12.4%) | -$9.82 M(-80.7%) |
| Dec 2016 | - | -$2.27 M(-26.5%) | -$50.87 M(+0.2%) |
| Sep 2016 | - | -$3.08 M(+60.3%) | -$50.75 M(-7.2%) |
| Jun 2016 | - | -$1.92 M(-95.6%) | -$54.69 M(-32.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2016 | -$46.44 M(+401.2%) | -$43.60 M(+1934.0%) | -$81.54 M(+95.3%) |
| Dec 2015 | - | -$2.14 M(-69.5%) | -$41.75 M(+4.7%) |
| Sep 2015 | - | -$7.02 M(-75.6%) | -$39.89 M(+16.4%) |
| Jun 2015 | - | -$28.78 M(+654.4%) | -$34.26 M(+269.7%) |
| Mar 2015 | -$9.27 M(+560.5%) | -$3.81 M(+1280.5%) | -$9.27 M(+37.2%) |
| Dec 2014 | - | -$276.30 K(-80.2%) | -$6.75 M(+13.3%) |
| Sep 2014 | - | -$1.39 M(-63.2%) | -$5.96 M(+5.0%) |
| Jun 2014 | - | -$3.78 M(+190.9%) | -$5.67 M(+304.7%) |
| Mar 2014 | -$1.40 M(-88.2%) | -$1.30 M(-352.1%) | -$1.40 M(-60.1%) |
| Dec 2013 | - | $516.00 K(-146.6%) | -$3.52 M(-61.2%) |
| Sep 2013 | - | -$1.11 M(-326.2%) | -$9.05 M(-6.2%) |
| Jun 2013 | - | $489.40 K(-114.3%) | -$9.65 M(-18.3%) |
| Mar 2013 | -$11.88 M(+15.2%) | -$3.41 M(-32.0%) | -$11.81 M(-9.8%) |
| Dec 2012 | - | -$5.02 M(+193.8%) | -$13.09 M(+8.0%) |
| Sep 2012 | - | -$1.71 M(+2.6%) | -$12.12 M(-0.8%) |
| Jun 2012 | - | -$1.67 M(-64.5%) | -$12.22 M(-0.1%) |
| Mar 2012 | -$10.31 M(>+9900.0%) | -$4.70 M(+16.1%) | -$12.23 M(+62.3%) |
| Dec 2011 | - | -$4.05 M(+124.0%) | -$7.53 M(+115.8%) |
| Sep 2011 | - | -$1.81 M(+7.6%) | -$3.49 M(+106.9%) |
| Jun 2011 | - | -$1.68 M(>+9900.0%) | -$1.69 M(>+9900.0%) |
| Mar 2011 | - | -$5300.00(+178.9%) | -$11.40 K(+28.1%) |
| Dec 2010 | -$8900.00(-59.5%) | -$1900.00(-9.5%) | -$8900.00(+6.0%) |
| Sep 2010 | - | -$2100.00(0.0%) | -$8400.00(+10.5%) |
| Jun 2010 | - | -$2100.00(-25.0%) | -$7600.00(0.0%) |
| Mar 2010 | - | -$2800.00(+100.0%) | -$7600.00(-65.5%) |
| Dec 2009 | -$22.00 K(+34.1%) | -$1400.00(+7.7%) | -$22.00 K(-34.5%) |
| Sep 2009 | - | -$1300.00(-38.1%) | -$33.60 K(+3.7%) |
| Jun 2009 | - | -$2100.00(-87.8%) | -$32.40 K(+3.2%) |
| Mar 2009 | - | -$17.20 K(+32.3%) | -$31.40 K(+91.5%) |
| Dec 2008 | -$16.40 K | -$13.00 K(>+9900.0%) | -$16.40 K(+382.4%) |
| Sep 2008 | - | -$100.00(-90.9%) | -$3400.00(+3.0%) |
| Jun 2008 | - | -$1100.00(-50.0%) | -$3300.00(-26.7%) |
| Mar 2008 | - | -$2200.00(-4.3%) | -$4500.00(0.0%) |
| Jun 2007 | - | -$2300.00(+4.5%) | -$4500.00(+104.5%) |
| Mar 2007 | - | -$2200.00 | -$2200.00 |
FAQ
- What is VistaGen Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for VistaGen Therapeutics?
- What is VistaGen Therapeutics annual EBIT year-on-year change?
- What is VistaGen Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for VistaGen Therapeutics?
- What is VistaGen Therapeutics quarterly EBIT year-on-year change?
- What is VistaGen Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for VistaGen Therapeutics?
- What is VistaGen Therapeutics TTM EBIT year-on-year change?
What is VistaGen Therapeutics annual earnings before interest & taxes?
The current annual EBIT of VTGN is -$33.02 M
What is the all time high annual EBIT for VistaGen Therapeutics?
VistaGen Therapeutics all-time high annual earnings before interest & taxes is -$8900.00
What is VistaGen Therapeutics annual EBIT year-on-year change?
Over the past year, VTGN annual earnings before interest & taxes has changed by +$26.25 M (+44.29%)
What is VistaGen Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of VTGN is -$15.12 M
What is the all time high quarterly EBIT for VistaGen Therapeutics?
VistaGen Therapeutics all-time high quarterly earnings before interest & taxes is $516.00 K
What is VistaGen Therapeutics quarterly EBIT year-on-year change?
Over the past year, VTGN quarterly earnings before interest & taxes has changed by -$2.99 M (-24.64%)
What is VistaGen Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of VTGN is -$52.84 M
What is the all time high TTM EBIT for VistaGen Therapeutics?
VistaGen Therapeutics all-time high TTM earnings before interest & taxes is -$2200.00
What is VistaGen Therapeutics TTM EBIT year-on-year change?
Over the past year, VTGN TTM earnings before interest & taxes has changed by -$14.68 M (-38.48%)